Cargando…

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer

Detalles Bibliográficos
Autores principales:	Nicolazzo, Chiara, Belardinilli, Francesca, Caponnetto, Salvatore, Gradilone, Angela, Cortesi, Enrico, Giannini, Giuseppe, Gazzaniga, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933952/ https://www.ncbi.nlm.nih.gov/pubmed/31921671 http://dx.doi.org/10.3389/fonc.2019.01414

Ejemplares similares

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
por: Nicolazzo, Chiara, et al.
Publicado: (2022)

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
por: Gazzaniga, Paola, et al.
Publicado: (2010)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer
por: Magri, Valentina, et al.
Publicado: (2023)

Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments
por: Nicolazzo, Chiara, et al.
Publicado: (2021)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study
por: Sciortino, Carolina, et al.
Publicado: (2022)

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal
por: Gradilone, Angela, et al.
Publicado: (2011)

Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Nicolazzo, Chiara, et al.
Publicado: (2017)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo
por: Raimondi, Cristina, et al.
Publicado: (2014)

Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

The Case for Brachytherapy: Why It Deserves a Renaissance
por: Williams, Vonetta M., et al.
Publicado: (2020)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Significance of Circulating Tumor Cells in Soft Tissue Sarcoma
por: Nicolazzo, Chiara, et al.
Publicado: (2015)

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
por: Abbosh, Christopher, et al.
Publicado: (2023)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden
por: Schneider, Charles J., et al.
Publicado: (2021)

Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma
por: Nicolazzo, Chiara, et al.
Publicado: (2018)

Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults
por: Liang, Jianfeng, et al.
Publicado: (2020)

Help for the Deserving
por: Lewisburg, J. H. M.
Publicado: (1876)

Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking
por: Cresswell, George D., et al.
Publicado: (2020)

Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2023)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Why Does Mental Health Not Get the Attention It Deserves? An Application of the Shiffman and Smith Framework
por: Tomlinson, Mark, et al.
Publicado: (2012)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

A Deserving Winner
por: Bhattacharya, Sanjoy
Publicado: (2014)

A Deserving Honor
Publicado: (1887)

Well-deserved Recognition
Publicado: (1897)

A Deserved Tribute
Publicado: (1918)

ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l5tldjdctc3nbh63b5756qn3o2